Drug class
Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor; preferential ROCK2 inhibitor
Mechanism of action
Inhibits ROCK2 more potently than ROCK1. Inhibition modulates pro-inflammatory responses through effects on STAT3/STAT5 phosphorylation and Th17/Treg balance and reduces aberrant profibrotic signalling; these actions are relevant to chronic graft-versus-host disease.
General use cases
- Treatment of adults and paediatric patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy under the current US product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
